Transforming growth factor β‐mediated micromechanics modulates disease progression in primary myelofibrosis-Reference-Cited by-同舟云学术

Transforming growth factor β‐mediated micromechanics modulates disease progression in primary myelofibrosis

Published:2020-09-05 Issue:19 Volume:24 Page:11100-11110
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J. Cell. Mol. Med.

Author:

Teodorescu Patric¹²,Pasca Sergiu¹,Jurj Ancuta³,Gafencu Grigore³⁴,Joelsson Jon‐Petur⁵⁶,Selicean Sonia³⁷,Moldovan Cristian⁸,Munteanu Raluca⁸,Onaciu Anca⁸,Tigu Adrian‐Bogdan⁸,Buse Mihail⁸,Zimta Alina‐Andreea⁸,Stiufiuc Rares⁸,Petrushev Bobe⁸,Desmirean Minodora¹⁹,Dima Delia¹⁰,Vlad Cristina¹¹¹²,Bergthorsson Jon Thor⁵⁶,Berce Cristian¹³,Ciurea Stefan¹⁴,Ghiaur Gabriel¹⁵^ORCID,Tomuleasa Ciprian¹²³^ORCID

Affiliation:

1. Department of Hematology Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca Romania

2. Department of Hematology Ion Chiricuta Clinical Cancer Center Cluj Napoca Romania

3. Research Center for Functional Genomics and Translational Medicine Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca Romania

4. Molecular Haematology Unit ‐ Weatherall Institute of Molecular Medicine John Radcliffe Hospital University of Oxford Oxford UK

5. Stem Cell Research Unit, Biomedical Center School of Health Sciences University of Iceland Reykjavík Iceland

6. Department of Laboratory Hematology Landspitali University Hospital Reykjavík Iceland

7. Graduate School for Cellular and Biomedical Sciences Universität Bern Bern Switzerland

8. Medfuture Research Center for Advanced Medicine Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca Romania

9. Department of Pathology Constantin Papilian Military Hospital Cluj Napoca Romania

10. Department of Hematology Ion Chiricuta Clinical Research Center Cluj Napoca Romania

11. Department of Cardiology Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca Romania

12. Department of Cardiology Rehabilitation Hospital Cluj Napoca Romania

13. Animal Facility Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca Romania

14. Department of Cellular Therapies and Stem Cell Transplantation University of Texas MD Anderson Cancer Center Houston TX USA

15. Department of Leukemia Sidney Kimmel Cancer Center at Johns Hopkins Johns Hopkins University School of Medicine Baltimore MD USA

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.15526

Reference61 articles.

1. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies

2. Myeloproliferative neoplasms: translating new discoveries into better outcomes, better quality of life;Padrnos L;Oncology (Williston Park),2017

3. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

4. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

5. MECOM,HBS1L-MYB,THRB-RARB, JAK2, andTERTpolymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases;Frontiers in Oncology;2023-02-23

2. In the Pipeline: Emerging Therapy for Classical Ph-Negative MPNs;Pathogenesis and Treatment of Leukemia;2023

3. Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study;Journal of Cancer Research and Clinical Oncology;2022-06-22

4. Cardiovascular Disease in Myeloproliferative Neoplasms;JACC: CardioOncology;2022-06

5. PEDF reduces malignant cells proliferation and inhibits the progression of myelofibrosis in myeloproliferative neoplasms;Biochemical Pharmacology;2022-05